Table 1.
Functional classification of gene targeted by RNAi | Intestinal gst-4p::gfp expression | mRNA (Figure 2 B) | Arsenite resistance | PMK-1 activation | Nuclear levels of SKN-1 S393A ::GFP | ||||
---|---|---|---|---|---|---|---|---|---|
WT (N2) (Additional file 1 : Table S3) | prdx-2 (Additional file 2 : Figure S3) | gcs-1 | gst-7 | (Figure 2 C) | (Figure 4 ) | (Figure 6 A) | |||
Gene expression | Human orthologue | Proposed function | |||||||
C17G10.1 | OGFOD1 | Regulates translation | - | - | ↓ | - | - | ↑ | - |
C35C5.1 sdc-2 | GOLGA6L5 | Sex determination/dosage compensation | ↓ | ND | ND | ND | ↓*** | ↑ | - |
F47A4.2 dpy-22 | MED12 | Mediator subunit | - | - | ↓* | ↓ | - | ↑ | - |
C16A3.8 thoc-2 | THOC2 | Transcriptional elongation | - | ↓*** | ↓*** | ↓* | ↓** | ↑ | ↓*** |
K04G7.11 | SYF2 | Pre-mRNA-splicing factor | - | ↓** | ↓ | ↑ | ↓ | ↑ | ↑*** |
Protein homeostasis | |||||||||
Y102A5A.1 cand-1 | CAND1 | Cullin-associated NEDD8-dissociated | - | ↓*** | ↓* | - | ↑* | ↑ | - |
B0025.2 csn-2 | CSN2 | Cop9 signalosome subunit | ↑ | ↓*** | ↓ | ↑*** | ↑* | - | ↑*** |
T05H10.5 ufd-2 | UBE4B | E4 ubiquitin conjugating enzyme | ↓ | ↓*** | ↓ | ↓* | ↓ | - | ↓*** |
Signal transduction | |||||||||
F13B10.1 tir-1 | SARM1 | Pathogen responses | - | ↓*** | ↓ | ↓* | ↓*** | ↓*** | - |
T28H11.2 srm-1 | - | Serpentine receptor | - | - | ↓** | - | ↓ | ↑ | - |
ZK792.3 inx-9 | - | Innexin | - | - | ND | ND | ND | ND | - |
Growth/metabolism | |||||||||
C06A8.1 mthf-1 | MTHFR | Methylenetetrahydrofolate reductase | - | ↓*** | ↓** | ↓* | ↓ | ↑ | - |
C34F11.3 | AMPD2 | AMP deaminase 2 | - | ↓*** | ND | ND | ND | ND | - |
Structural | |||||||||
F46E10.11 hpo-26 | - | Hypersensitive to pore-forming toxin | - | ↓*** | ND | ND | ↓ | ↑ | ↑*** |
Transport/trafficking | |||||||||
R11A5.1 apb-3 | AP3B1/2 | Adaptin | - | - | ↓** | ↑*** | - | ↑ | ↑*** |
Unknown function | |||||||||
F22F7.4 | - | - | - | ↓* | ↓* | - | - | - |
Sixteen RNAi that prevented any detectable intestinal gcs-1p::gfp expression in prdx-2 mutant animals and in more than 50% of wild-type animals treated with 1 mM arsenite for 90 min (N2 gcs-1p::gfp) on each of three occasions on which they were screened, following quantitative analysis, but which did not reduce intestinal expression of a non-phase 2 reporter gene, F09E5.3::gfp (Additional file 1: Table S3). These genes were placed into categories based on gene ontology [15]. Where RNAi affected gst-4p::gfp expression in wild-type (Additional file 1: Table S3) or prdx-2 mutant animals (Additional file 2: Figure S3) the effect is indicated by an arrow. Where RNAi produced a greater than 10% change in gcs-1 or gst-7 mRNA levels in arsenite-treated animals (Figure 2B), arsenite resistance (Figure 2A,C), PMK-1 phosphorylation in arsenite-treated animals (Figure 4) or levels of SKN-1S393A::GFP in intestinal nuclei (Figure 6A) this is indicated. Statistically significant differences from control animals are indicated (*P < 0.05; **P < 0.01; ***P < 0.001). ND, not determined; RNAi, RNA interference; WT, wild type.